97 件 ・ 関連度順
概要と使いどころ
Use when positioning an ACM CCS submission against the security big-four and specialist literature, including arXiv preprints, prior CCS/S&P/USENIX/NDSS papers, concurrent disclosures, CVE and advisory records, and the attack-and-defense lineage that a SIGSAC program committee expects to see credited.
日本語の概要は準備中です。原文の説明を表示しています。
Use when designing or auditing ACM CCS experiments, attack demonstrations, adaptive-attack defense evaluations, security measurements, baselines, overhead and cost reporting, ablations, and claim-to-evidence fit, with emphasis on evidence that survives an adversarial program committee rather than leaderboard wins.
日本語の概要は準備中です。原文の説明を表示しています。
Use when deciding whether a security project fits ACM CCS versus IEEE S&P, USENIX Security, NDSS, PETS, or a crypto/theory venue, identifying the security contribution type, and sharpening the threat model and attacker capability before writing begins.
日本語の概要は準備中です。原文の説明を表示しています。
Use when preparing ACM CCS appendices and supplementary material, including the ethics considerations appendix, protocol transcripts, formal proofs, measurement tables, and anonymized supporting material under the 12-page body limit, anonymity, and reviewer-discretion constraints for a security paper.
日本語の概要は準備中です。原文の説明を表示しています。
Use when drafting an ACM CCS rebuttal during the HotCRP author-response window, covering threat-model defenses, adaptive-attack objections, ethics and disclosure questions, anonymity constraints, adversarial reviewer pushback patterns, and decision-focused replies aimed at the meta-reviewer.
日本語の概要は準備中です。原文の説明を表示しています。
Queries gnomAD v4 (807k samples), v3, v2.1.1, and constraint metrics with grpmax FAF95, bottleneck-group exclusion, LOEUF interpretation, SV/CNV/mtDNA catalogs, and Whiffin max-credible-AF framework. Use when filtering rare variants, applying ACMG BS1/BA1, ranking genes by LoF intolerance, or selecting between v2 (GRCh37 + chrX/Y constraint) and v4 (GRCh38 + 807k samples).
日本語の概要は準備中です。原文の説明を表示しています。
Queries ClinVar for variant pathogenicity classifications, ClinGen VCEP curations, and somatic-vs-germline interpretations via REST API, weekly VCF, or bulk XML. Use when determining clinical significance, triangulating conflicting interpretations, or aggregating evidence against the ACMG/AMP framework with ClinGen SVI specifications.
日本語の概要は準備中です。原文の説明を表示しています。
Implements missing-data sensitivity analyses for confirmatory clinical trials including MMRM under MAR (with Kenward-Roger correction), reference-based multiple imputation (J2R, CR, CIR, LMCF per Carpenter-Roger 2013), Permutt delta-adjustment / tipping-point analysis, pattern-mixture identifying restrictions (CCMV, NCMV, ACMV), and the Cro vs Bartlett variance debate. Use when handling missing primary or secondary endpoint data in regulatory submissions following NRC 2010 and ICH E9(R1).
日本語の概要は準備中です。原文の説明を表示しています。
Predicts whether a DNA variant alters mRNA splicing using sequence-based deep-learning tools — SpliceAI (10kb context dilated CNN, clinical default), Pangolin (multi-tissue), MMSplice (modular per-region CNN with calibrated ΔPSI), SpliceTransformer/TrASPr (tissue-aware transformers), SpliceVault (empirical 300K-RNA lookup of likely mis-splicing outcomes), CADD-Splice (composite score). Applies the ClinGen SVI 2023 framework for ACMG/AMP variant interpretation (PVS1, PP3, BP4 evidence codes), HGVS splicing nomenclature (c.123+1G>A, c.123-3T>G, r.spl?), extended-window scoring for deep-intronic pseudoexons, tissue-specific predictions, branchpoint variant detection (BPHunter, LaBranchoR), and splice-switching ASO design. Use when interpreting splice impact of clinical variants, prioritizing VUS, identifying deep-intronic pathogenic variants, or designing ASOs.
日本語の概要は準備中です。原文の説明を表示しています。
Switch the active brand profile for agency work and confirm the new context. "change brand to Acme"
日本語の概要は準備中です。原文の説明を表示しています。
Switch the active credential profile to another client, validating keys first, approval-gated. "activate Acme's API keys"
日本語の概要は準備中です。原文の説明を表示しています。
Agents should invoke this skill for academic or technical papers, arXiv/PubMed/IEEE/ACM links, PDFs, methodology review, limitations, practical implications, or extracting findings for engineering decisions.
日本語の概要は準備中です。原文の説明を表示しています。
Provides AWS CloudFormation patterns for CloudFront distributions, origins (ALB, S3, Lambda@Edge, VPC Origins), CacheBehaviors, Functions, SecurityHeaders, parameters, Outputs and cross-stack references. Use when creating CloudFront distributions with CloudFormation, configuring multiple origins, implementing caching strategies, managing custom domains with ACM, configuring WAF, and optimizing performance.
日本語の概要は準備中です。原文の説明を表示しています。
Provides AWS CloudFormation patterns for security infrastructure including KMS encryption, Secrets Manager, IAM security, VPC security, ACM certificates, parameter security, outputs, and secure cross-stack references. Use when implementing security best practices, encrypting data, managing secrets, applying least privilege IAM policies, securing VPC configurations, managing TLS/SSL certificates, and implementing defense in depth strategies.
日本語の概要は準備中です。原文の説明を表示しています。
Publication-figure overlay for draw.io. Use instead of drawio whenever the diagram is for a paper, thesis, dissertation, journal, conference, IEEE/ACM submission, manuscript, camera-ready, Word/LaTeX figure, or other publication. Applies venue, figure-type, color, caption/legend, formula, and paper-readability gates for architecture, workflow, roadmap, network-topology, and replicated paper figures.
日本語の概要は準備中です。原文の説明を表示しています。
Fix cert-manager DNS01 ACME challenges stuck in "pending" state with "DNS record not yet propagated" inside GKE private clusters, even when TXT records exist in Cloudflare DNS. Use when: (1) cert-manager challenges show "pending" for hours with propagation check failures, (2) dig from outside cluster shows correct TXT records but cert-manager can't verify them, (3) Using Cloudflare DNS01 solver in a GKE private cluster with Cloud NAT, (4) Google Cloud intercepts 8.8.8.8 DNS queries returning NXDOMAIN for Cloudflare-managed records, (5) Even --dns01-recursive-nameservers with 1.1.1.1 doesn't fix the propagation check despite TXT records being verifiable from busybox pods in the same namespace. Covers the full debugging flow and certbot manual workaround.
日本語の概要は準備中です。原文の説明を表示しています。
Think and work like an expert Medical Geneticist. Use when a task calls for Medical Geneticist judgment. Reasons from pedigree priors, HPO phenotype match, and ACMG/ClinGen variant classification; integrates exome/genome, CMA, RNA splicing, NBS ACT pathways, Tier 3 carrier screening, SF v3.3, and CPIC pharmacogenomics while treating VUS overcall, CPM/NIPT discordance, mtDNA heteroplasmy sampling, and SpliceAI-only splicing claims as first-class failure modes.
日本語の概要は準備中です。原文の説明を表示しています。
Think and work like an expert Molecular Geneticist. Use when a task calls for Molecular Geneticist judgment. Reasons from sequence-as-hypothesis, reference context (genome build, MANE/RefSeq transcript, HGVS), and allele-level molecular consequence through ACMG/AMP-ClinGen criteria, IGV/VEP/SpliceAI/gnomAD/ClinVar review, MIQE-compliant qPCR/ddPCR, and Sanger/NGS validation while treating allele dropout, pseudogene/paralog misalignment, FFPE deamination, contamination and barcode bleed, and transcript/build mismatch as first-class failure modes.
日本語の概要は準備中です。原文の説明を表示しています。
Think and work like an expert Genomicist. Use when a task calls for Genomicist judgment. Reasons from reference-relative coordinates, haplotypes, variant classes, and sequencing-as-measurement through GATK/DeepVariant, VEP/ClinVar/gnomAD, GIAB/hap.py benchmarking, and ACMG/AMP-ClinGen frameworks while treating build mismatches, paralog/pseudogene and GC dropout artifacts, contamination and index hopping, batch effects, and annotation drift as first-class failure modes.
日本語の概要は準備中です。原文の説明を表示しています。
Think and work like an expert Geneticist. Use when a task calls for Geneticist judgment. Reasons from particulate inheritance, segregation, recombination, allele frequency, and genotype-phenotype evidence through ACMG/AMP-ClinGen classification, gnomAD/ClinVar/OMIM, HPO phenotyping, and PLINK/GATK/VEP QC while treating sample swaps, cryptic relatedness, population stratification, LD tagging, phenocopies, winner's curse, and build/transcript mismatch as first-class failure modes.
日本語の概要は準備中です。原文の説明を表示しています。
Think and work like an expert Genetic Counselor. Use when a task calls for Genetic Counselor judgment. Reasons from probabilistic penetrance, Bayesian pretest probability, and patient autonomy through three-generation pedigrees, ACMG/AMP variant criteria, ClinVar/ClinGen/gnomAD, NCCN and CPIC guidelines, and cascade-testing protocols while treating VUS over-upgraded to pathogenic, screening-versus-diagnostic confusion (NIPT vs amnio/CVS), and unaddressed psychosocial and GINA discrimination risk as first-class failure modes.
日本語の概要は準備中です。原文の説明を表示しています。
Think and work like an expert Cytogeneticist. Use when a task calls for Cytogeneticist judgment. Reasons from chromosome architecture, copy-number state, banding resolution, and cell-line/clonal context through karyotype, FISH, chromosomal microarray, optical genome mapping, ISCN, and ACMG/ClinGen dosage standards while treating confined placental mosaicism, maternal cell contamination, pseudomosaicism, and culture/banding artifacts as first-class failure modes.
日本語の概要は準備中です。原文の説明を表示しています。
Queries ClinVar for variant pathogenicity classifications, ClinGen VCEP curations, and somatic-vs-germline interpretations via REST API, weekly VCF, or bulk XML. Use when determining clinical significance, triangulating conflicting interpretations, or aggregating evidence against the ACMG/AMP framework with ClinGen SVI specifications.
日本語の概要は準備中です。原文の説明を表示しています。
Clinical variant interpretation using ClinVar, ACMG guidelines, and pathogenicity predictors. Prioritize variants for diagnostic and research applications. Use when interpreting clinical significance of variants.
日本語の概要は準備中です。原文の説明を表示しています。